Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?

× No keyword cloud information.

14 in total

Review 1. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Authors: André J Scheen
Journal: Clin Pharmacokinet Date: 2017-07 Impact factor: 6.447

Review 2. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.

Authors: Karly P Garnock-Jones
Journal: Drugs Date: 2017-03 Impact factor: 9.546

Review 3. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.

Authors: Esther S Kim; Emma D Deeks
Journal: Drugs Date: 2015-09 Impact factor: 9.546

4. DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.

Authors: Francesco Paneni
Journal: Cardiovasc Diagn Ther Date: 2015-12

5. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

Authors: Yutaka Seino; Kohei Kaku; Takashi Kadowaki; Taro Okamoto; Asako Sato; Masayoshi Shirakawa; Edward A O'Neill; Samuel S Engel; Keith D Kaufman
Journal: Diabetes Obes Metab Date: 2021-02-28 Impact factor: 6.577

6. SGLT2 inhibitors: the latest "new kids on the block"!

Authors: William T Cefalu; Matthew C Riddle
Journal: Diabetes Care Date: 2015-03 Impact factor: 19.112

Review 7. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.

Authors: Sayf A Yassin; Vanita R Aroda
Journal: Drug Des Devel Ther Date: 2017-03-21 Impact factor: 4.162

8. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).

Authors: K M Dungan; R Weitgasser; F Perez Manghi; E Pintilei; J L Fahrbach; H H Jiang; J Shell; K E Robertson
Journal: Diabetes Obes Metab Date: 2016-02-19 Impact factor: 6.577

9. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.

Authors: Yotsapon Thewjitcharoen; Nalin Yenseung; Areeya Malidaeng; Soontaree Nakasatien; Phawinpon Chotwanvirat; Sirinate Krittiyawong; Ekgaluck Wanothayaroj; Thep Himathongkam
Journal: Diabetol Metab Syndr Date: 2017-12-01 Impact factor: 3.320

Review 10. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.

Authors: Huan Yu; Vincent C Woo
Journal: Diabetes Metab Syndr Obes Date: 2017-07-21 Impact factor: 3.168